Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Eben Soliz

Physician Assistant Cedar Park, TX Physician Assistant

NPI 1003043662 CMS profile 11240527

1401 Medical Pkwy Bldg B Ste 200, Cedar Park, TX 78613

Open in the dashboard

General payments

$8,010

333 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eben Soliz of Cedar Park, TX is reported in the CMS Open Payments database as having received $8,010 across 333 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,111 42
2024 General $2,409 95
2023 General $1,934 78
2022 General $1,604 68
2021 General $953 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eben Soliz
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Eben Soliz were reported at $1,111. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Eben Soliz Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $953 $132 $37–$438 $132
2022 $1,604 $155 $48–$522 $149
2023 $1,934 $167 $52–$557 $160
2024 $2,409 $178 $55–$600 $164
2025 $1,111 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Regeneron Healthcare Solutions, Inc. $1,607 46 payments
  2. AstraZeneca Pharmaceuticals LP $1,593 49 payments
  3. GlaxoSmithKline, LLC. $1,202 72 payments
  4. Genzyme Corporation $682 32 payments
  5. Amgen Inc. $555 30 payments
  6. Novartis Pharmaceuticals Corporation $431 20 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $403 18 payments
  8. CSL Behring $195 9 payments
  9. Grifols USA, LLC $164 8 payments
  10. ALK-Abello, Inc $158 8 payments
  11. Other $1,020 41 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,925 331 payments
  2. Education $85 2 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Inflammation And Immunology $1,267 34 payments
  2. TEZSPIRE Respiratory $911 18 payments
  3. DUPIXENT Immunology $899 44 payments
  4. TRELEGY ELLIPTA $644 47 payments
  5. TEZSPIRE Inflammation $555 30 payments
  6. FASENRA $528 21 payments
  7. NUCALA $437 23 payments
  8. XOLAIR $400 18 payments
  9. AIRSUPRA $327 10 payments
  10. CUVITRU $300 13 payments
  11. Other $2,638 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

1,181

Median for Physician Assistant: 241

Drug cost

$810,889

Median for Physician Assistant: $4,110

Branded share of claims

50.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 45 $203,831
Dupixent Syringe Dupilumab Brand 50 $181,589
Nucala Mepolizumab Brand 34 $128,224
Fasenra Pen Benralizumab Brand 13 $72,207
Xolair Omalizumab Brand 12 $54,445
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 44 $36,080
Spiriva Respimat Tiotropium Bromide Brand 19 $18,385
Breo Ellipta Fluticasone/Vilanterol Brand 31 $17,031
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 23 $16,961
Symbicort Budesonide/Formoterol Fumarate Brand 50 $16,065

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$7,928

Of which drugs: $2,745

Medicare patients

53

Average age 73

Services billed

274

33 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 57%
Ischemic heart disease 34%
COPD 28%
Osteoporosis 28%
Atrial fibrillation 25%
Depression 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $530
  • GENZYME CORPORATION $166
$696 95 —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $167
  • Amgen Inc. $130
$297 — —
XOLAIR
  • Novartis Pharmaceuticals Corporation $258
  • Genentech USA, Inc. $21
$279 12 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $219
$219 — —
NUCALA
  • GlaxoSmithKline, LLC. $133
$133 34 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

333 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record